患者様やご家族など一般の方向け臨床・治癒情報サイト 臨床研究情報ポータルサイト

ENGLISH
×

情報をクリップできます

治験情報をこちらのホームページで一時的にクリップすることが出来ます。

海外の治験の状況「1」での検索結果

絞り込み

224件の検索結果
  • 進捗状況
  • 試験名
  • 対象疾患名
  • 地域
  • 登録日
  •  
  • Authorised

  • Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease
  • Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
  • Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
  • 2018-01-31
  • Authorised

  • Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease
  • Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
  • Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
  • 2018-01-30
  • Authorised

  • Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s Disease
  • Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
  • Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
  • 2018-01-30
  • Authorised

  • Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to treat Metastatic Breast Cancer (PATINA)
  • HR+/HER2+ metastatic breast cancer MedDRA version: 20.0 Level: PT Classification code 10065430 Term: HER-2 positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, Germany, Italy, New Zealand, Spain, United States
  • 2017-10-23
  • Authorised

  • Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resection
  • Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-transit metastases) MedDRA version: 20.0 Level: PT Classification code 10025670 Term: Malignant melanoma stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Russian Federation, Serbia, Singapore, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States
  • 2015-04-21
  • Authorised

  • Phase 3 1L Study of Pembrolizumab ± Ipilimumab in NSCLC
  • Metastatic programmed cell deathligand 1 (PD-L1) positive (TPS =50%) non-small cell lung cancer (NSCLC) MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Italy, Korea, Republic of, Latvia, Mexico, New Zealand, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
  • 2017-09-14
  • Authorised

  • Phase 3 1L Study of Pembrolizumab ± Ipilimumab in NSCLC
  • Metastatic programmed cell deathligand 1 (PD-L1) positive (TPS =50%) non-small cell lung cancer (NSCLC) MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Italy, Korea, Republic of, Latvia, Mexico, New Zealand, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
  • 2017-09-05
  • Authorised

  • Phase 3 1L Study of Pembrolizumab ± Ipilimumab in NSCLC
  • Metastatic programmed cell deathligand 1 (PD-L1) positive (TPS =50%) non-small cell lung cancer (NSCLC) MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Italy, Korea, Republic of, Latvia, Mexico, New Zealand, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
  • 2017-09-01